1. What Mdl Proceedings Are and How They Differ from Class Actions
MDL proceedings and class actions are the two primary mechanisms for resolving mass civil litigation, and they are frequently confused because both involve large numbers of plaintiffs pursuing similar claims against the same defendant.
In a class action, one or a few named plaintiffs litigate on behalf of a certified class, and a single verdict or settlement binds every class member who did not opt out. The case proceeds as a single action with a single set of claims. In an MDL proceeding, each plaintiff retains their individual lawsuit. The MDL consolidates those individual cases for pretrial purposes only. Discovery is coordinated, expert testimony is shared, and motions are briefed once for all plaintiffs, but each plaintiff's claims, defenses, and damages remain distinct. There is no certification hearing, no predominance requirement, and no right to opt out of the MDL transfer itself.
The practical consequence is that an MDL plaintiff who is unhappy with the global settlement can reject it and proceed to individual trial, while a class member who did not opt out is bound by the class settlement regardless of their personal preference.
How the Jpml Decides Where to Send an Mdl and Who Gets to Preside
The Judicial Panel on Multidistrict Litigation is a seven-judge body that evaluates petitions to create an MDL, selects the transferee district, and designates the transferee judge who will manage all pretrial proceedings.
A party seeking to create an MDL files a motion to transfer with the JPML arguing that the pending cases share common questions of fact and that consolidation will produce efficiencies that justify transfer. The JPML evaluates the number and geographic distribution of pending cases, the court's capacity to manage complex litigation, the convenience of the parties, and whether the cases are sufficiently similar to benefit from coordination. The JPML has significant discretion in its selection of both the transferee district and the transferee judge, and its decisions are not appealable in the ordinary course.
The transferee judge assumes complete control over all pretrial proceedings, including discovery, expert witness management, dispositive motions, and bellwether trial scheduling. In practice, the selection of the transferee judge is one of the most consequential aspects of the MDL formation process because that judge's management style, views on Daubert challenges to expert testimony under Federal Rule of Evidence 702, and approach to settlement pressure shape the entire litigation's trajectory. An attorney who handles mass torts and MDL proceedings can evaluate which district and which judge would be most favorable given the specific liability and damages profile of the case.
| Feature | Mdl Proceeding | Class Action |
|---|---|---|
| Individual cases | Each plaintiff keeps their own case | Single class action on behalf of all |
| Certification required | No | Yes, under Rule 23 |
| Binding settlement | Must individually accept | Binds all who did not opt out |
| Governing statute | 28 U.S.C. § 1407 | Fed. R. Civ. P. 23 |
2. How Mdl Proceedings Are Structured from Transfer through Trial
MDL proceedings follow a recognizable sequence of phases that applies across virtually every MDL, from pharmaceutical products liability to securities fraud to mass disaster litigation, and understanding where the case is in that sequence determines what decisions are immediately relevant.
The early phase of an MDL involves the establishment of the case management structure. The transferee judge appoints a Plaintiffs' Steering Committee from among the plaintiffs' attorneys who have filed cases in the MDL, and that committee assumes responsibility for coordinating discovery, filing joint motions, and negotiating with defendants on behalf of all plaintiffs. The judge issues a comprehensive case management order setting the schedule for discovery, expert disclosures, Daubert briefing, and bellwether trial selection.
Common discovery covers the evidence relevant to all plaintiffs, including the defendant's internal documents about the product or conduct at issue, corporate witness depositions, and regulatory submissions. Individual discovery covering each plaintiff's specific medical history, damages, and causation is typically conducted on a separate track and is often deferred until after the common discovery phase is complete.
How the Plaintiffs' Steering Committee Manages Cases on Everyone'S Behalf
The Plaintiffs' Steering Committee is the leadership structure that coordinates pretrial work across all individual cases, and its decisions bind all MDL plaintiffs without requiring their individual consent for each litigation choice.
The PSC negotiates with defense counsel on discovery protocols, expert witness schedules, and trial management, and it makes strategic decisions about which arguments to advance and which to abandon. PSC members are typically compensated from a common benefit fund, which assesses a percentage of each individual plaintiff's recovery to pay for the shared pretrial work that benefits all cases. The common benefit assessment is approved by the MDL judge and is taken from individual settlements before distribution to the plaintiff, typically ranging from 4 to 7 percent of individual recoveries.
Individual plaintiffs whose cases are part of the MDL have limited ability to control the PSC's litigation decisions, but they retain the right to reject any settlement offer and to object to any PSC fee application at the time of final distribution. An attorney who handles product liability and mass torts and MDL cases can advise individual plaintiffs on which decisions require their personal authorization and which are made collectively by the PSC.
The common benefit fund assessment in an MDL is paid from each plaintiff's individual recovery, not by the defendant separately. A plaintiff who receives a $100,000 individual settlement and is subject to a 6 percent common benefit assessment will net $94,000 before their own attorney's contingency fee is deducted. Understanding the layers of deduction from an individual recovery, including the common benefit assessment, individual counsel's contingency, any costs advanced by counsel, and any liens from medical providers or government payors, is essential before any plaintiff accepts a settlement offer.
3. What Bellwether Trials Determine for Every Plaintiff in Mdl Proceedings
Bellwether trials are the mechanism through which an MDL generates the factual and legal findings that inform the valuation of thousands of individual cases that will never go to trial themselves, and they are the defining feature that distinguishes MDL proceedings from both class actions and ordinary mass tort litigation.
The transferee judge selects a small group of individual cases, typically four to eight, that are representative of the broader MDL plaintiff population and schedules them for trial in sequence. Each bellwether trial is a fully contested individual trial with its own jury, its own damages evidence, and its own verdict. The results of the bellwether trials reveal what juries in the transferee district are willing to award for specific injury categories, whether the defendant's liability arguments resonate with lay jurors, and whether the plaintiffs' expert testimony survives Daubert challenges.
The information generated by bellwether verdicts gives both sides a factual basis for evaluating the entire MDL's settlement value, because the same liability facts and similar damages profiles apply across most of the individual cases. A defendant that loses three consecutive bellwether trials faces the prospect of thousands of additional verdicts using the same fact pattern and the same jury pool, which creates powerful pressure to negotiate a global settlement.
How Global Settlements in Mdl Proceedings Distribute Money to Individual Plaintiffs
A global MDL settlement is a defendant's agreement to pay a total sum to resolve some or all pending individual cases, with the distribution among plaintiffs determined by a points-based allocation formula that the PSC and defendant negotiate and the MDL judge approves.
The allocation matrix assigns point values to different injury categories, severity levels, duration of exposure, age, and other factors that determine relative damages across the plaintiff population. A plaintiff with a more severe injury, a longer exposure period, or stronger individual causation evidence receives a higher point allocation and a proportionally larger share of the settlement fund. The matrix is designed to approximate what individual plaintiffs would receive from individualized litigation, but no allocation formula perfectly replicates what individual trials would produce.
Individual plaintiffs must affirmatively accept a global settlement offer, and a minimum percentage of plaintiffs, typically 85 to 95 percent, must accept before the defendant's settlement obligation becomes effective. A plaintiff who rejects the global settlement retains their individual case and can proceed to trial, but they lose access to the settlement fund and must litigate against a defendant that has already settled with thousands of other plaintiffs. An attorney who handles pharmaceutical litigation and MDL global settlement matters can evaluate whether an individual plaintiff's specific injury profile is fairly captured by the allocation matrix before advising on acceptance.
An individual plaintiff who rejects a global MDL settlement and proceeds to trial faces a defendant with full access to all discovery, all expert reports, and all trial transcripts developed during the MDL pretrial proceedings, while the individual plaintiff must conduct their own individual discovery at their own cost with their own attorney. The information asymmetry between a well-resourced defendant and an individual plaintiff outside the MDL settlement is substantial, and that asymmetry is one of the primary reasons global settlement acceptance rates consistently exceed 90 percent in major MDL proceedings.
4. Frequently Asked Questions about Mdl Proceedings
MDL proceedings generate a specific category of questions from plaintiffs who have just learned their case was transferred, from individuals trying to determine whether their injury is part of an active MDL, and from people evaluating whether to accept or reject a global settlement offer. Those questions are addressed here.
What Is an Mdl Proceeding and How Does It Differ from a Class Action?
An MDL proceeding is a federal procedural mechanism under 28 U.S.C. § 1407 that consolidates thousands of similar individual lawsuits before a single transferee judge for coordinated pretrial proceedings. Unlike a class action, each plaintiff in an MDL retains their own individual case, their own claims, and their own right to accept or reject any settlement offer. A class action binds all class members who did not opt out, while an MDL global settlement requires each plaintiff's affirmative acceptance. The MDL is fundamentally a case management tool, not a merits determination that binds anyone automatically.
What Is a Bellwether Trial and How Does It Affect My Individual Case?
A bellwether trial is a fully contested individual trial selected by the MDL judge as representative of the broader plaintiff population, conducted to generate jury verdict data that informs the valuation of all remaining cases. Your individual case is not tried in a bellwether trial unless it is specifically selected, but the results of bellwether trials directly affect what your case is worth in a global settlement because they reveal what juries are willing to award for similar injuries caused by the same conduct. A defendant that loses multiple bellwether trials faces settlement pressure to resolve the remaining cases at values consistent with those verdicts.
What Is the Plaintiffs' Steering Committee and Who Does It Represent?
The Plaintiffs' Steering Committee is a group of plaintiffs' attorneys appointed by the MDL judge to coordinate pretrial work across all individual cases, including common discovery, expert witnesses, and negotiations with the defendant. It represents the collective interests of all MDL plaintiffs but is not your individual attorney. Your individual attorney retains responsibility for advising you on individual decisions including settlement acceptance, while the PSC handles the shared litigation work that benefits all plaintiffs. PSC members are compensated from a common benefit fund assessed against individual recoveries, typically 4 to 7 percent.
Can I Reject a Global Mdl Settlement and Still Pursue My Case?
Yes. Global MDL settlements require each plaintiff's individual acceptance, and a plaintiff who rejects the offer retains their individual case. However, rejection means the plaintiff must litigate individually against a defendant with full access to all MDL pretrial work, without the resources of the PSC, and without access to the settlement fund. Most defendants condition their global settlement obligation on a minimum acceptance threshold of 85 to 95 percent of plaintiffs, so mass rejection can collapse the settlement entirely. Individual plaintiffs with atypically strong or severe cases sometimes negotiate enhanced individual settlements outside the global matrix.
How Is Money Distributed to Individual Plaintiffs in a Global Mdl Settlement?
The global settlement fund is distributed to individual plaintiffs through an allocation matrix that assigns point values to different injury categories, severity levels, exposure duration, and other factors. Each plaintiff's point allocation determines their proportional share of the fund. The points-based approach is designed to approximate individualized damages without requiring individual trials for each of thousands of plaintiffs. Before any settlement proceeds reach a plaintiff, deductions are taken for the common benefit fund assessment, individual counsel's contingency fee, costs advanced by counsel, and any outstanding medical liens or government subrogation claims.
How Does My Individual Case Return to Its Original Court after the Mdl Ends?
If your case is not resolved through a global settlement or individual trial in the MDL, it can be remanded to the transferee district under 28 U.S.C. § 1407 for trial on the individual merits. Remand occurs at the conclusion of pretrial proceedings when the transferee judge determines that the coordinated work is complete. The case returns to the federal district where it was originally filed, bringing with it the pretrial record developed in the MDL. An attorney who handles complex litigation and MDL proceedings can advise on whether remand or individual settlement is the more favorable path for a specific plaintiff whose case was not captured by the global resolution.
28 May, 2026
